JP2005517016A - αＬβ２インテグリン介在細胞接着阻害剤 - Google Patents

αＬβ２インテグリン介在細胞接着阻害剤 Download PDF

Info

Publication number
JP2005517016A
JP2005517016A JP2003566009A JP2003566009A JP2005517016A JP 2005517016 A JP2005517016 A JP 2005517016A JP 2003566009 A JP2003566009 A JP 2003566009A JP 2003566009 A JP2003566009 A JP 2003566009A JP 2005517016 A JP2005517016 A JP 2005517016A
Authority
JP
Japan
Prior art keywords
acceptable salt
compound
salt
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003566009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517016A5 (https=
Inventor
イラ・サーカー
マーシャル・モーニングスター
正甫 角嶋
秀文 鍛冶
隆行 川口
俊行 久米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2005517016A publication Critical patent/JP2005517016A/ja
Publication of JP2005517016A5 publication Critical patent/JP2005517016A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2003566009A 2002-02-07 2003-02-06 αＬβ２インテグリン介在細胞接着阻害剤 Ceased JP2005517016A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07
PCT/US2003/003449 WO2003066636A1 (en) 2002-02-07 2003-02-06 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

Publications (2)

Publication Number Publication Date
JP2005517016A true JP2005517016A (ja) 2005-06-09
JP2005517016A5 JP2005517016A5 (https=) 2005-12-22

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003566009A Ceased JP2005517016A (ja) 2002-02-07 2003-02-06 αＬβ２インテグリン介在細胞接着阻害剤

Country Status (23)

Country Link
US (1) US7375128B2 (https=)
EP (1) EP1472257B1 (https=)
JP (1) JP2005517016A (https=)
KR (1) KR100625379B1 (https=)
CN (1) CN1301255C (https=)
AR (1) AR040068A1 (https=)
AT (1) ATE411995T1 (https=)
AU (1) AU2003210862B2 (https=)
BR (1) BR0307521A (https=)
CA (1) CA2474748A1 (https=)
CO (1) CO5601028A2 (https=)
DE (1) DE60324250D1 (https=)
EC (1) ECSP045222A (https=)
MX (1) MXPA04007643A (https=)
MY (1) MY137878A (https=)
NO (1) NO20043563L (https=)
NZ (1) NZ534208A (https=)
PE (1) PE20030899A1 (https=)
PL (1) PL372328A1 (https=)
RU (1) RU2315768C2 (https=)
TW (1) TW200303200A (https=)
WO (1) WO2003066636A1 (https=)
ZA (1) ZA200405647B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516949A (ja) * 2011-05-09 2014-07-17 エフ．ホフマン−ラ ロシュ アーゲー 新規ヘキサヒドロピロロイミダゾロン化合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US20080262070A1 (en) * 2005-10-06 2008-10-23 Karl Baumann Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
EP3969066B1 (en) * 2019-05-16 2025-08-20 Dispensing Dynamics International, Inc. Fragrance dispenser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
US6251902B1 (en) 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
PT1307455E (pt) * 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2
IL152922A0 (en) * 2000-05-23 2003-06-24 Histatek Llc Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516949A (ja) * 2011-05-09 2014-07-17 エフ．ホフマン−ラ ロシュ アーゲー 新規ヘキサヒドロピロロイミダゾロン化合物

Also Published As

Publication number Publication date
ATE411995T1 (de) 2008-11-15
CN1301255C (zh) 2007-02-21
ECSP045222A (es) 2006-04-19
EP1472257B1 (en) 2008-10-22
DE60324250D1 (de) 2008-12-04
KR20040091625A (ko) 2004-10-28
TW200303200A (en) 2003-09-01
EP1472257A1 (en) 2004-11-03
CA2474748A1 (en) 2003-08-14
MY137878A (en) 2009-03-31
PL372328A1 (en) 2005-07-11
KR100625379B1 (ko) 2006-09-20
US7375128B2 (en) 2008-05-20
PE20030899A1 (es) 2003-10-25
WO2003066636A1 (en) 2003-08-14
US20050171174A1 (en) 2005-08-04
RU2004123219A (ru) 2006-02-10
AU2003210862B2 (en) 2006-10-26
AU2003210862A1 (en) 2003-09-02
BR0307521A (pt) 2004-12-28
RU2315768C2 (ru) 2008-01-27
NZ534208A (en) 2005-12-23
NO20043563L (no) 2004-11-01
ZA200405647B (en) 2005-07-15
MXPA04007643A (es) 2005-06-08
AR040068A1 (es) 2005-03-16
CO5601028A2 (es) 2006-01-31
CN1628116A (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
JP3943394B2 (ja) αＬβ２介在細胞接着阻害剤
RU2686117C1 (ru) Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf
JP2010521513A (ja) アザ−ピリドピリミジノン誘導体
US6710064B2 (en) Hydantoin compounds useful as anti-inflammatory agents
EP1603917B1 (en) Immunomodulating heterocyclic compounds
AU2001253538B2 (en) Inhibitors of alpha l beta 2 mediated cell adhesion
JP2005517016A (ja) αＬβ２インテグリン介在細胞接着阻害剤
EP2509981B1 (en) Inhibitors of diacylglycerol acyltransferase
US8481750B2 (en) Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides
JP4109890B2 (ja) 医薬組成物
CA2380852C (en) Tricyclic compounds having spiro union
SK3242000A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
JP2005068145A (ja) 医薬組成物
JPH09104674A (ja) アズレン誘導体およびその製造方法ならびにタキキニン受容体拮抗剤
JP3022693B2 (ja) テトラヒドロピロロ〔１，２−ａ〕ピラジン−４−スピロ−３′−ピロリジン類及び中間体
AU2004220310B2 (en) Immunomodulating heterocyclic compounds
JP2004519435A (ja) 抗炎症性薬物として有用なヒダントイン化合物
HK1053473B (en) Inhibitors of alpha-l beta-2 mediated cell adhesion

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090331

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20090728